Palladiem’s Gilead Sciences GILD Stock Holding History

Palladiem’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.4K	Hold	19	–	–	﹤0.01%	117
2026 Q1	$2.64K	Hold	19	–	–	﹤0.01%	131
2025 Q4	$2.33K	Buy	+19	New	+$2.31K	﹤0.01%	140

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Palladiem's GILD Position: Q2 2026 in Review

Palladiem held its Gilead Sciences (GILD) position steady in Q2 2026 at 19 shares worth $2.4K. The position accounts for ﹤0.01% of the portfolio, ranked #117.

Palladiem first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.64K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Palladiem held 19 shares of Gilead Sciences worth $2.4K as of Q2 2026.
Palladiem left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up ﹤0.01% of Palladiem's portfolio in Q2 2026, its #117 holding.
Palladiem first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
Palladiem's Gilead Sciences position peaked at $2.64K in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Palladiem's 13F filing for Q2 2026, filed 13 Aug 2026.